TianYu Bio-Technology Co., Ltd. (SHA:603717)
China · Delayed Price · Currency is CNY 6.70
+0.16 (2.45%)
Sep 7, 2026, 3:00 PM CST
TianYu Bio-Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 657.18 | 718.82 | 794.5 | 668.39 | 940.87 | 633.77 |
Other Revenue | 6.77 | 6.77 | 7 | 2.06 | 4.04 | 4.31 |
| 663.95 | 725.59 | 801.51 | 670.45 | 944.91 | 638.08 | |
Revenue Growth | -16.00% | -9.47% | 19.55% | -29.05% | 48.09% | 9.53% |
Cost of Revenue | 758.25 | 756.17 | 732.8 | 990.07 | 859.29 | 588.92 |
Gross Profit | -94.31 | -30.58 | 68.71 | -319.62 | 85.62 | 49.16 |
Selling, General & Admin | 79.72 | 84.84 | 110 | 95.41 | 88.53 | 97.09 |
Research & Development | 9.63 | 13.16 | 11.29 | 13.91 | 26.38 | 10.37 |
Other Operating Expenses | 1.63 | 2.07 | 1.17 | 1.35 | 7.61 | 3.98 |
Operating Expenses | 83.89 | 92.98 | 144.47 | 114.76 | 354.67 | 283.67 |
Operating Income | -178.19 | -123.56 | -75.76 | -434.38 | -269.05 | -234.52 |
Interest Expense | -53.34 | -53.34 | -36.53 | -30.56 | -29.18 | -48.76 |
Interest & Investment Income | 60.63 | 46.23 | 29.9 | 11.67 | 19.71 | 37.52 |
Currency Exchange Gain (Loss) | 0.03 | 0.03 | 0.09 | 0 | - | - |
Other Non Operating Income (Expenses) | 1.01 | -4.18 | -1.27 | -0.51 | -31.16 | -9.28 |
EBT Excluding Unusual Items | -169.87 | -134.81 | -83.57 | -453.77 | -309.68 | -255.04 |
Impairment of Goodwill | -0.56 | -0.56 | -5 | - | - | - |
Gain (Loss) on Sale of Investments | 2.4 | 4.52 | -0.43 | -109.7 | -25.28 | - |
Gain (Loss) on Sale of Assets | 0.01 | 25.97 | -0.67 | 0.99 | 47.44 | 8.81 |
Asset Writedown | -20.38 | -1.85 | -2.92 | -14.97 | -1.4 | -0.41 |
Other Unusual Items | 9.23 | 9.23 | 1.27 | -3.85 | 9.78 | 10.94 |
Pretax Income | -177.91 | -96.23 | -87.16 | -578.58 | -278.22 | -235.7 |
Income Tax Expense | 7.59 | 5.79 | -0.32 | -12.69 | -42.51 | -15.14 |
Earnings From Continuing Operations | -185.5 | -102.02 | -86.84 | -565.89 | -235.71 | -220.56 |
Minority Interest in Earnings | 13.4 | -4.89 | -20.51 | 104.25 | -43.7 | 5.82 |
Net Income | -172.1 | -106.9 | -107.36 | -461.64 | -279.41 | -214.74 |
Net Income to Common | -172.1 | -106.9 | -107.36 | -461.64 | -279.41 | -214.74 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 290 | 290 | 290 | 290 | 242 | 266 |
Shares Outstanding (Diluted) | 290 | 290 | 290 | 290 | 242 | 266 |
Shares Change | -0.02% | 0.01% | - | 19.99% | -9.09% | 9.99% |
EPS (Basic) | -0.59 | -0.37 | -0.37 | -1.59 | -1.16 | -0.81 |
EPS (Diluted) | -0.59 | -0.37 | -0.37 | -1.59 | -1.16 | -0.81 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 131.12 | 204.82 | 81.27 | -260.48 | 22.19 | -230.25 |
Free Cash Flow Per Share | 0.45 | 0.71 | 0.28 | -0.90 | 0.09 | -0.87 |
Gross Margin | -14.20% | -4.21% | 8.57% | -47.67% | 9.06% | 7.70% |
Operating Margin | -26.84% | -17.03% | -9.45% | -64.79% | -28.47% | -36.75% |
Profit Margin | -25.92% | -14.73% | -13.39% | -68.85% | -29.57% | -33.66% |
Free Cash Flow Margin | 19.75% | 28.23% | 10.14% | -38.85% | 2.35% | -36.09% |
EBITDA | -131.24 | -81.95 | -37.79 | -401.97 | -254.53 | -220.24 |
EBITDA Margin | -19.77% | -11.29% | -4.71% | -59.95% | -26.94% | -34.52% |
D&A For EBITDA | 46.96 | 41.61 | 37.98 | 32.41 | 14.52 | 14.27 |
EBIT | -178.19 | -123.56 | -75.76 | -434.38 | -269.05 | -234.52 |
EBIT Margin | -26.84% | -17.03% | -9.45% | -64.79% | -28.47% | -36.75% |
Revenue as Reported | 725.59 | 725.59 | 801.51 | 670.45 | 944.91 | 638.08 |
Advertising Expenses | - | 0.17 | 0.21 | 0.02 | 0.01 | 0.25 |